Close Menu

private financing

NGeneBio Raises $11M

The company has also achieved a CE-IVD mark for its HemeAccuTest, which targets hematological malignancies.

The company is developing a single-molecule sequencing technology intended to significantly reduce the cost and improve the accuracy of sequencing.

The company said it will use the funds to expand its operations in Ireland, which it established through the recent acquisition of Genomics Medicine Ireland.

The firm's technology uses DNA sequencing, artificial intelligence, and a microbial database to interpret soil health and identify potential disease risk.

The firm will use the funding to advance commercialization of its RNA disruption assay and continue its breast cancer response therapy trial.

The award comes after DNAe completed the first phase of a contract valued at up to $51.9 million, which BARDA initiated in September 2016.

The company offers kits and services based on a synthetic long-read sequencing technology that enables short-read sequencers to generate long-read data.

Menlo Park, California-based Clear Labs, which raised a combined $19.5 million in Series A and B financing rounds, has raised $45 million to date.

The firm said it will use the financing to continue marketing its Engineered Cells and CRISPRevolution product lines and to expand in Europe and Asia.

Berkeley Lights markets the Beacon platform — a light-based nanofluidics platform for single-cell selection, characterization, culture, and export.

Pages

Nature News reports that genomics is being applied to trace and try to prevent additional COVID-19 waves.

Rady's Children Hospital and San Diego County are teaming up to test pediatric patients and their families for COVID-19 to gauge the spread of the virus locally, according to the San Diego Union-Tribune.

Wildlife managers aim to boost the genetic diversity of Mexican gray wolves by placing captive-born foster pups into packs with similarly aged wild pups, the Mercury News reports.

In Science this week: Genetic Probability tool identifies likely diagnoses in 45 percent of inflammatory arthritis cases, and more.